- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06053645
O peso das doenças cardiovasculares
O peso da doença cardiovascular: um estudo piloto prospectivo de adultos obesos com doença cardiovascular avaliados em uma nova clínica cardiometabólica
The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients referred to the cardiometabolic clinic at Mayo Clinic Hospital in Rochester, MN will be recruited for participation.
Descrição
Inclusion Criteria:
- BMI ≥30 kg/m2
- At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
- Patients evaluated in the Cardiometabolic clinic
- Willingness to complete questionnaires/surveys
- Ability to complete monthly self-assessments at home
Exclusion Criteria:
- BMI <30 kg/m2
- Pregnancy or lactating women
- Hemodynamically unstable CVD
- Active malignancy
- Autoimmune or systemic inflammatory diseases
- Severe renal or hepatic failure
- Being considered unsafe to participate as determined by the study physician
- Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
- Patients with active psychosis, mania, or substance use disorders
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent body weight loss
Prazo: 12 months
|
Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss. |
12 months
|
|
Change in Body Mass Index (BMI)
Prazo: Baseline, 12 months
|
Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703 |
Baseline, 12 months
|
|
Change in visceral adiposity distribution
Prazo: Baseline, 12 months
|
Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA). |
Baseline, 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Blood Pressure
Prazo: Baseline, 12 months
|
Measured in millimeters of mercury (mmHg) |
Baseline, 12 months
|
|
Change in point of care glucose
Prazo: Baseline, 12 months
|
Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing. |
Baseline, 12 months
|
|
Change in quality of diet
Prazo: Baseline, 12 months
|
Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D)
Prazo: Baseline, 12 months
|
Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R)
Prazo: Baseline, 12 months
|
Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire
Prazo: Baseline, 12 months
|
Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress. |
Baseline, 12 months
|
|
Change in functional aerobic capacity (VO2 Max)
Prazo: Baseline, 12 months
|
VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test |
Baseline, 12 months
|
|
Change in artificial intelligence electrocardiogram (AI-ECG) age
Prazo: Baseline, 12 months
|
AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs). |
Baseline, 12 months
|
|
Change in E/e'
Prazo: Baseline, 12 months
|
E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in Peak Tricuspid Regurgitation (TR) Velocity
Prazo: Baseline, 12 months
|
Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in Right Atrial (RA) Pressure
Prazo: Baseline, 12 months
|
RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in Left Atrial (LA) volume index
Prazo: Baseline, 12 months
|
LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in physical activity
Prazo: Baseline, 12 months
|
Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in heart rate with detection of arrhythmia
Prazo: Baseline, 12 months
|
Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in cardio fitness
Prazo: Baseline, 12 months
|
Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in six-minute walk test
Prazo: Baseline, 12 months
|
Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale
Prazo: Baseline, 12 months
|
The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress. |
Baseline, 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kyla Lara-Breitinger, M.D., Mayo Clinic
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 26-008806
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .